| Latest Vastox Plc News Headlines |
| Date | Time | Source | |
| 07/24/2007 | 2:40AM | TFNF | Summit, Evolva Biotech sign 3 yr infectious disease research project
British biotechnology group Summit Corporation
PLC, until last week called VASTox, has signed a three-year agreement with
Evolva Biotech SA to develop new drugs for infectious diseases.
The collaboration covers Summit's immunomodulator drug candidate SMT14400
and backup compounds from the company's proprietary... More...>> |
| 07/19/2007 | 7:28AM | TFNF | VASTox says shareholders give nod for issue of new shares
Biotechnology company VASTox PLC said it has
been granted authority to issue new shares up to a nominal value of one mln stg.
The company also said non-executive chairman Barry Price and chief
commercial officer James Taylor were re-elected to the board of directors, at
its annual general meeting.
VASTox... More...>> |
| 07/19/2007 | 6:02AM | UKREG | Result of AGM
VASTox plc
19 July 2007
VASTox plc
("VASTox" or "the Company")
Results of Annual General Meeting
Oxford, UK, 19 July 2007 - VASTox plc (AIM: VOX), a leading UK biotechnology
company, announces that at today's Annual General... More...>> |
| 07/02/2007 | 4:00AM | RNSNON | Details of R&D Day - 24 July
VASTox plc
02 July 2007
VASTox plc
("VASTox" or "the Company")
VASTOX TO HOST R&D DAY ON 24 JULY 2007 IN LONDON
Oxford, UK, 2 July 2007 - VASTox plc (AIM: VOX), a leading UK biotechnology
company, is planning to hold an... More...>> |
| 06/29/2007 | 7:06AM | UKREG | Notice of AGM
VASTox plc
29 June 2007
VASTox plc
("VASTox" or "the Company")
ANNUAL REPORT AVAILABLE - NOTICE OF AGM
Oxford, UK, 29 June 2007 - VASTox plc (AIM: VOX), a leading UK biotechnology
company, today announces that its Annual Report... More...>> |
| 06/28/2007 | 6:04AM | UKREG | Notice of AGM
VASTox plc
28 June 2007
VASTox plc
("VASTox" or "the Company")
NOTICE OF ANNUAL GENERAL MEETING
Oxford, UK, 28 June 2007 - VASTox plc (AIM: VOX), a leading UK biotechnology
company, today announces that its Annual Report... More...>> |
| 06/27/2007 | 3:58AM | TFNF | VASTox signs pilot screening deals worth over 300,000 eur
VASTox PLC said it signed pilot screening deals
worth in excess of 300,000 eur in service revenues with major pharmaceutical
companies, including Merck KGaA, Johnson & Johnson and Servier.
The signing of these deals provides it an opportunity to further validate
its technology platform, zebrafish, the company... More...>> |
| 06/27/2007 | 2:01AM | UKREG | Re Agreement
VASTox plc
27 June 2007
VASTox plc
("VASTox" or "the Company")
VASTOX ANNOUNCES SIGNIFICANT PROGRESS IN PHARMACEUTICAL SERVICES BUSINESS
* Pilot screening deals signed in zebrafish platform with top tier
pharmaceutical companies worth... More...>> |
| 06/20/2007 | 3:34AM | TFNF | VASTox says wins 400,000 stg grant from Welsh Develpment Agency
Biotechnology company VASTox PLC said it won a
400,000 stg grant from the Welsh Development Agency to support its research and
development work at its Aberystwyth facility.
The company said the grant, which runs for 12 months, was awarded under the
SMARTCymru scheme.
TFN.newsdesk@thomson.com
rda/jlc
COPYRIGHT
Copyright... More...>> |
| 06/20/2007 | 2:01AM | UKREG | Grant Funding
VASTox plc
20 June 2007
VASTox plc
("VASTox" or "the Company")
VASTOX AWARDED #400,000 GRANT TO SUPPORT R&D
AT CARBOHYDRATE CHEMISTRY FACILITY
Oxford, UK, 20 June 2007 - VASTox plc (AIM: VOX... More...>> |
| 05/29/2007 | 4:25AM | TFNF | VASTox annual losses widen UPDATE
(Adds further detail)
VASTox PLC reported widening annual losses as
the UK biotechnology company, which focuses on neuro-disorders and infectious
diseases, almost tripled spending on research and development.
In the 12 months to end-Jan pretax losses widened to 3.5 mln from 1.2 mln in
the same period... More...>> |
| 05/29/2007 | 2:37AM | TFNF | VASTox annual losses widen
VASTox PLC reported widening annual losses as
the UK biotechnology company, which focuses on neuro-disorders and infectious
diseases, almost tripled spending on research and development.
In the 12 months to end-Jan pretax losses widened to 3.5 mln from 1.2 mln in
the same period the previous year... More...>> |
| 05/29/2007 | 2:02AM | UKREG | Final Results
VASTox plc
29 May 2007
VASTox plc
("VASTox" or "the Company")
PRELIMINARY RESULTS FOR THE YEAR ENDED 31 JANUARY 2007
Oxford, UK, 29 May 2007 - VASTox plc (AIM: VOX), a leading UK biotechnology
company, today announces its preliminary... More...>> |
| 05/29/2007 | 1:20AM | TFNF | Thomson Financial Europe AM at a glance share guide: Stocks up, dollar mixed
US SUMMARY: Stocks rise; dollar mixed
Index Change Pct change
*DJIA 13507.28 +66.15 +0.49
*Nasdaq 2557.19 +19.27 +0.76
*S&P 500 1515.73 + 8.22 +0.55
Dow Future 13527.00 +47.00 +0.35 (2014 GMT)
Nasdaq... More...>> |
| 05/23/2007 | 5:36AM | TFNF | VASTox to start next phase of trials for Parkinson symptom drugs
VASTox PLC said it is preparing to start the
next phase of clinical trials in its neuro-disorder programmes, which target two
symptoms of Parkinson's disease, following positive results from initial phase I
studies.
The biotechnology company said initial phase I studies showed the small
molecule drug candidates... More...>> |
| 05/23/2007 | 2:02AM | RNSNON | Clinical Development
VASTox plc
23 May 2007
VASTox plc
("VASTox" or "the Company")
VASTOX PREPARES TO COMMENCE NEXT PHASE OF CLINICAL DEVELOPMENT FOR TWO LEADING
NEURO-DISORDER DRUG PROGRAMMES
Progress follows earlier... More...>> |
| 05/22/2007 | 2:01AM | UKREG | Notice of Results
VASTox plc
22 May 2007
VASTox plc
("VASTox" or "the Company")
NOTICE OF PRELIMINARY RESULTS FOR THE YEAR ENDED 31 JANUARY 2007
Oxford, UK, 22 May 2007 - VASTox plc (AIM: VOX), a leading UK biotechnology
company, will announce its preliminary... More...>> |
| 05/16/2007 | 3:22AM | TFNF | VASTox signs carbohydrate drug development deal with an unnamed US company
VASTox PLC said it has signed a carbohydrate
drug development deal with an undisclosed US pharmaceutical company.
The biotechnology company said it will receive development payments of
450,000 usd a majority of which will appear in the current financial year and a
5 pct annual royalty fee starting in 2009... More...>> |
| 05/16/2007 | 2:01AM | UKREG | Re Agreement
VASTox plc
16 May 2007
VASTox plc
("VASTox" or "the Company")
VASTOX SIGNS CARBOHYDRATE DRUG DEVELOPMENT DEAL WITH US PHARMACEUTICAL COMPANY
$450,000 Development Payment and 5% Royalty on Annual Sales
Oxford, UK, 16 May 2007... More...>> |
| 05/08/2007 | 4:30AM | TFNF | VASTox selects drug candidate for treatment of genetic muscular diseases
Biotechnology company VASTox PLC said it has
selected a pre-clinical drug candidate VOX C1100 to develop a drug to be used in
the treatment of Duchenne Muscular Dystrophy (DMD).
The company said it expects to submit an investigational new drug filing for
VOX C1100 by mid 2008 with the compound entering first-in-man... More...>> |